{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:36:40Z","timestamp":1787002600301,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2006,3,1]]},"DOI":"10.1038\/ncponc0430","type":"journal-article","created":{"date-parts":[[2006,3,6]],"date-time":"2006-03-06T23:13:10Z","timestamp":1141686790000},"page":"165-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab"],"prefix":"10.1038","volume":"3","author":[{"given":"Stephanie","family":"Halene","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Zieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Berliner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncponc0430_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1365-2141.2005.05570.x","volume":"130","author":"SD Gibbs","year":"2005","unstructured":"Gibbs SD et al. (2005) Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br J Haematol 130: 87\u201391","journal-title":"Br J Haematol"},{"key":"BFncponc0430_CR2","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S0140-6736(74)90553-4","volume":"1","author":"G Frizzera","year":"1974","unstructured":"Frizzera G et al. (1974) Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet 1: 1070\u20131073","journal-title":"Lancet"},{"key":"BFncponc0430_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S0140-6736(88)90367-4","volume":"1","author":"AG Stansfeld","year":"1988","unstructured":"Stansfeld AG et al. (1988) Updated Kiel classification for lymphomas. Lancet 1: 292\u2013293","journal-title":"Lancet"},{"key":"BFncponc0430_CR4","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES et al. (Eds; 2001) World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. Lyon: IARC Press"},{"key":"BFncponc0430_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1097\/00125480-200209000-00001","volume":"9","author":"JA Ferry","year":"2002","unstructured":"Ferry JA (2002) Angioimmunoblastic T-cell lymphoma. Adv Anat Pathol 9: 273\u2013279","journal-title":"Adv Anat Pathol"},{"key":"BFncponc0430_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1046\/j.1365-2141.2003.04335.x","volume":"121","author":"A Dogan","year":"2003","unstructured":"Dogan A et al. (2003) Angioimmunoblastic T-cell lymphoma. Br J Haematol 121: 681\u2013691","journal-title":"Br J Haematol"},{"key":"BFncponc0430_CR7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.7326\/0003-4819-117-5-364","volume":"117","author":"W Siegert","year":"1992","unstructured":"Siegert W et al. (1992) Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM\/IMVP-16 regimen: a multicenter study. Ann Intern Med 117: 364\u2013370","journal-title":"Ann Intern Med"},{"key":"BFncponc0430_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3109\/10428199909058412","volume":"32","author":"P Pautier","year":"1999","unstructured":"Pautier P et al. (1999) Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 32: 545\u2013552","journal-title":"Leuk Lymphoma"},{"key":"BFncponc0430_CR9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/10428190290016926","volume":"43","author":"M Reiser","year":"2002","unstructured":"Reiser M et al. (2002) T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma 43: 805\u2013811","journal-title":"Leuk Lymphoma"},{"key":"BFncponc0430_CR10","first-page":"1272","volume":"88","author":"J Schetelig","year":"2003","unstructured":"Schetelig J et al. (2003) Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 88: 1272\u20131278","journal-title":"Haematologica"},{"key":"BFncponc0430_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/10428190210190","volume":"43","author":"C Strupp","year":"2002","unstructured":"Strupp C et al. (2002) Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leuk Lymphoma 43: 133\u2013137","journal-title":"Leuk Lymphoma"},{"key":"BFncponc0430_CR12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2165\/00003495-200363120-00003","volume":"63","author":"JE Frampton","year":"2003","unstructured":"Frampton JE and Wagstaff AJ (2003) Alemtuzumab. Drugs 63: 1229\u20131243","journal-title":"Drugs"},{"key":"BFncponc0430_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1586\/14737140.5.1.39","volume":"5","author":"F Ravandi","year":"2005","unstructured":"Ravandi F and O'Brien S (2005) Alemtuzumab. Expert Rev Anticancer Ther 5: 39\u201351","journal-title":"Expert Rev Anticancer Ther"},{"key":"BFncponc0430_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1365-2141.2005.05570.x","volume":"130","author":"SD Gibbs","year":"2005","unstructured":"Gibbs SD et al. (2005) Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br J Haematol 130: 87\u201391","journal-title":"Br J Haematol"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncponc0430","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncponc0430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncponc0430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T09:06:25Z","timestamp":1744275985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc0430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,1]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3,1]]}},"alternative-id":["BFncponc0430"],"URL":"https:\/\/doi.org\/10.1038\/ncponc0430","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,1]]},"assertion":[{"value":"31 August 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}